A blood based entire body screen to find HPV induced cancer early - all within minutes and by using just one drop of blood
Rapid test for detecting HPV16 induced carcinomas early. Easy to use in doctor's practice.
Clinical specificity > 99%
Learn more about screening for HPV induced cancer in the white paper series "Guidelines for identifying high-risk patients"
Interactive training resources on early detection of HPV-induced carcinomas
Moving from cell to blood based HPV cancer screening.
Abviris offers a new patented generation of Immune Oncology Diagnostics for early detection of HPV induced cancer, allowing a blood based entire body screen within minutes just using one drop of blood.
News
AND THE WINNER IS…
Abviris Deutschland GmbH has been awarded “Pilot of the Year“ by the UK Diagnostics Summit 2019. This prestigious award was presented at the summit on 28 November 2019 in Manchester. High-ranking representatives of the National Health Service (NHS), diagnostics industry and the British IVD Association (BIVDA) honoured the results of a pilot study into the …
New evidence demonstrates the potential of Prevo-Check® and tumour marker DRH1® for early detection of HPV-induced diseases
Our product Prevo-Check®, a patented test for the detection of HPV16-induced tumours, is the focus of two studies to be presented at the international HPV (human papilloma virus) congress EUROGIN on December 4-7. In a study conducted at the University of Graz, Dr. Weiland and colleagues discovered that Prevo-Check® is a rapid test for identifying …
Investors Convinced of Potential and Importance of a Novel Cancer Management Concept
Abviris GmbH Obtains Almost 3 Million Euros in Pre-Series A Financing Abviris GmbH commenced market entry in Germany after successful test-marketing phase (450 customers, 300,000 € revenues) and, respective clinical trials. Initial positioning is targeting screening for HPV induced tumours of head and neck and the anogenital region. Funds raised in round A reveal that …
